L1CAM and neoplasm: This means that the FL-L1CAM-mediated pro-metastatic effect was detectable in different metastatic secondary sites as well as with different tumour entities (solid epithelial, solid mesenchymal, and haematological malignancies), ruling out strict organ- and cell line-specificity.